Singapore-based Aslan Pharmaceuticals is hitting go again on its stalled dermatitis study. Back in April, ASLAN004, the biotech's anti-IL-13Rα1 antibody licensed from CSL and positioned to try to take ...
Aslan Pharmaceuticals has been hit by the news that its lead drug varlitinib missed the mark in a gastric cancer trial, sending its shares down almost 16%. The Singapore biotech says its phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results